Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

NCT04545710 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Abemaciclib
DRUG: Osimertinib

Sponsor

University of California, San Diego

Collaborators

[object Object]